RxDoctor Payments Data

Stacey Hollaway, MD

Internal Medicine · Canton, OHNPI 1922064906

Payments from drug & device makers

$15,489in general payments, 2019–2025

Across 922 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • GSK$918
  • Lilly USA, LLC$701
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,481100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)212$3,010
Novo Nordisk103$1,712
AstraZeneca61$1,386
Pfizer98$1,105
GSK60$918
Lilly USA, LLC51$701
Supernus Pharmaceuticals, Inc.27$461
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$449
Takeda Pharmaceuticals U.S.A., Inc.28$406
Bayer18$393
Boehringer Ingelheim19$359
Amgen(2 entities)12$303
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$276
Gilead10$275
Ironshore Pharmaceuticals Inc.10$272
Exact Sciences14$265
Phathom Pharmaceuticals, Inc.5$259
Corium, LLC9$258
Sanofi Pasteur Inc.10$215
Idorsia Pharmaceuticals US Inc7$200
Astellas Pharma US Inc12$191
Almatica Pharma LLC10$181
Sanofi-aventis U.S. LLC12$174
Otsuka America Pharmaceutical, Inc.10$138
Abbott2$114
Merck8$105
Eisai Inc.5$104
Novartis4$78
Aimmune Therapeutics, Inc.4$75
Johnson & Johnson6$74
Genentech USA, Inc.4$73
Xeris Pharmaceuticals, Inc.4$66
Biohaven Pharmaceutical Holding Company Ltd.4$64
Optinose US, Inc.3$57
Nestle Healthcare Nutrition Inc.3$56
Corcept Therapeutics2$47
Amarin Pharma, Inc.3$44
IBSA Pharma Inc.3$44
Axsome Therapeutics, Inc.2$38
Vivus LLC2$36
Collegium Pharmaceutical, Inc.2$35
VBI Vaccine (delaware) Inc.2$34
Inspire Medical Systems, Inc.2$34
E.r. Squibb & Sons, L.L.C.2$33
Lundbeck LLC2$32
Ironwood Pharmaceuticals, Inc2$30
Tris Pharma Inc2$29
Teva Pharmaceuticals USA, Inc.2$29
Currax Pharmaceuticals LLC2$27
Radius Health, Inc.2$26
Adlon Therapeutics L.p.2$26
Grifols USA, LLC1$22
Ardelyx, Inc.1$20
Biohaven Pharmaceuticals, Inc.1$20
Dermira, Inc.1$19
Vertical Pharmaceuticals, LLC1$18
Sumitomo Pharma America, Inc.1$16
Neos Therapeutics, LP1$16
Noven Therapeutics, LLC1$15
Seqirus USA Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,489 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$70,023
Medicare patients
197
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$114,329
FarxigaDapagliflozin Propanediol112$90,070
EliquisApixaban56$52,186
TrulicityDulaglutide45$49,593
JardianceEmpagliflozin69$48,767
Synjardy XrEmpagliflozin/Metformin Hcl36$26,056
MounjaroTirzepatide16$21,613
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,978
XareltoRivaroxaban16$18,976
MyrbetriqMirabegron21$17,280
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$16,264
EntrestoSacubitril/Valsartan13$14,208
TrintellixVortioxetine Hydrobromide14$13,402
KerendiaFinerenone16$13,158
RybelsusSemaglutide12$11,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,712$126,018108 claims
AstraZenecaFarxiga$1,386$90,070112 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$359$82,182117 claims
Lilly USA, LLCTrulicity, Mounjaro$701$71,20661 claims
PfizerEliquis$1,105$52,18656 claims
GSKTrelegy Ellipta, Anoro Ellipta$918$28,34338 claims
Johnson & JohnsonXarelto$74$18,97616 claims
Astellas Pharma US IncMyrbetriq$191$17,28021 claims
NovartisEntresto$78$14,20813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$406$13,40214 claims
BayerKerendia$393$13,15816 claims
AbbVieSynthroid$3,010$2,03166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →